Literature DB >> 22807579

Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.

Pierre Saintigny1, Shaohua Peng, Li Zhang, Banibrata Sen, Ignacio I Wistuba, Scott M Lippman, Luc Girard, John D Minna, John V Heymach, Faye M Johnson.   

Abstract

The Eph family of receptors is the largest family of receptor tyrosine kinases, but it remains poorly studied in lung cancer. We aimed to systematically explore the human Eph receptors and their ligands, the ephrins, in lung adenocarcinoma. The prognostic impact of Eph receptor and ephrin gene expression was analyzed using 2 independent cohorts of lung adenocarcinoma. Gene expression profiles in lung adenocarcinoma compared with normal adjacent lung were studied in 3 independent cohorts and in cell lines. Gene expression profiles were validated with quantitative polymerase chain reaction (qPCR) and Western blotting in cell lines. Functional studies to assess the role of Eph receptor A4 (EphA4) were carried out in vitro. The biological effects of EphA4 in lung cancer cell lines were assayed following overexpression and knockdown. Of the 11 Eph receptors and 8 ephrins analyzed, only EphA4 and ephrin A1 gene expression were consistently associated with an improved outcome in patients with lung adenocarcinoma. Expression levels of EphA4 by microarray correlated well with expression levels measured by qPCR and Western blotting. EphA4 overexpression reduced cell migration and invasion but did not affect cell cycle, apoptosis, or drug sensitivity. Surprisingly, EphA4 was expressed at higher levels in cancer compared with non-cancer tissues and cell lines. EphA4 gene expression is associated with an improved outcome in patients with resected lung adenocarcinoma, possibly by affecting cancer cell migration and invasion. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22807579      PMCID: PMC3438283          DOI: 10.1158/1535-7163.MCT-12-0030

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  52 in total

Review 1.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

2.  Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.

Authors:  Haina Qin; Jiahai Shi; Roberta Noberini; Elena B Pasquale; Jianxing Song
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

3.  Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.

Authors:  Roberta Noberini; Mitchell Koolpe; Satyamaheshwar Peddibhotla; Russell Dahl; Ying Su; Nicholas D P Cosford; Gregory P Roth; Elena B Pasquale
Journal:  J Biol Chem       Date:  2008-08-26       Impact factor: 5.157

4.  Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer.

Authors:  Jian Gong; Asahiro Morishita; Kazutaka Kurokohchi; Joji Tani; Kiyohito Kato; Hisaaki Miyoshi; Hideyuki Inoue; Mitsuyoshi Kobayashi; Shi Liu; Masayuki Murota; Akemi Muramatsu; Kunihiko Izuishi; Yasuyuki Suzuki; Hirohito Yoshida; Naohito Uchida; Kazushi Deguchi; Hisakazu Iwama; Ichiro Ishimaru; Tsutomu Masaki
Journal:  Int J Oncol       Date:  2010-01       Impact factor: 5.650

5.  Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies.

Authors:  A E G Lenferink; C Cantin; A Nantel; E Wang; Y Durocher; M Banville; B Paul-Roc; A Marcil; M R Wilson; M D O'Connor-McCourt
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

6.  EphA2 in the early pathogenesis and progression of non-small cell lung cancer.

Authors:  Jennifer M Brannan; Banibrata Sen; Babita Saigal; Ludmila Prudkin; Carmen Behrens; Luisa Solis; Wenli Dong; B Nebiyou Bekele; Ignacio Wistuba; Faye M Johnson
Journal:  Cancer Prev Res (Phila)       Date:  2009-11-24

7.  EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.

Authors:  Hui Miao; Da-Qiang Li; Amitava Mukherjee; Hong Guo; Aaron Petty; Jennifer Cutter; James P Basilion; John Sedor; Jiong Wu; David Danielpour; Andrew E Sloan; Mark L Cohen; Bingcheng Wang
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

8.  Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.

Authors:  Jennifer M Brannan; Wenli Dong; Ludmila Prudkin; Carmen Behrens; Reuben Lotan; B Nebiyou Bekele; Ignacio Wistuba; Faye M Johnson
Journal:  Clin Cancer Res       Date:  2009-06-16       Impact factor: 12.531

9.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

Authors:  Martin L Sos; Kathrin Michel; Thomas Zander; Jonathan Weiss; Peter Frommolt; Martin Peifer; Danan Li; Roland Ullrich; Mirjam Koker; Florian Fischer; Takeshi Shimamura; Daniel Rauh; Craig Mermel; Stefanie Fischer; Isabel Stückrath; Stefanie Heynck; Rameen Beroukhim; William Lin; Wendy Winckler; Kinjal Shah; Thomas LaFramboise; Whei F Moriarty; Megan Hanna; Laura Tolosi; Jörg Rahnenführer; Roel Verhaak; Derek Chiang; Gad Getz; Martin Hellmich; Jürgen Wolf; Luc Girard; Michael Peyton; Barbara A Weir; Tzu-Hsiu Chen; Heidi Greulich; Jordi Barretina; Geoffrey I Shapiro; Levi A Garraway; Adi F Gazdar; John D Minna; Matthew Meyerson; Kwok-Kin Wong; Roman K Thomas
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

10.  EphA4 as an effector of Twist1 in the guidance of osteogenic precursor cells during calvarial bone growth and in craniosynostosis.

Authors:  Man-Chun Ting; Nancy L Wu; Paul G Roybal; Jingjing Sun; Liqiong Liu; Youzhen Yen; Robert E Maxson
Journal:  Development       Date:  2009-03       Impact factor: 6.868

View more
  24 in total

1.  Oxidative stress associates with aggressiveness in lung large-cell carcinoma.

Authors:  Leonardo Lisboa da Motta; Marco Antonio De Bastiani; Fernanda Stapenhorst; Fábio Klamt
Journal:  Tumour Biol       Date:  2015-02-01

2.  Identification of Potential Gene Network Associated with HCV-Related Hepatocellular Carcinoma Using Microarray Analysis.

Authors:  Yang Cheng; Jian Ping; Jianjie Chen
Journal:  Pathol Oncol Res       Date:  2017-07-01       Impact factor: 3.201

3.  EBV, an inhibited receptor kinase, and lymphoma.

Authors:  Richard F Ambinder
Journal:  Blood       Date:  2016-09-22       Impact factor: 22.113

Review 4.  EphB4: A promising target for upper aerodigestive malignancies.

Authors:  Ravi Salgia; Prakash Kulkarni; Prakash S Gill
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 10.680

Review 5.  Eph receptors and ephrins: therapeutic opportunities.

Authors:  Antonio Barquilla; Elena B Pasquale
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-03       Impact factor: 13.820

6.  Prospective Proteomic Study Identifies Potential Circulating Protein Biomarkers for Colorectal Cancer Risk.

Authors:  Xiaohui Sun; Xiao-Ou Shu; Qing Lan; Monika Laszkowska; Qiuyin Cai; Nathaniel Rothman; Wanqing Wen; Wei Zheng; Xiang Shu
Journal:  Cancers (Basel)       Date:  2022-07-03       Impact factor: 6.575

7.  Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Authors:  Jihye Kim; Vihas T Vasu; Rangnath Mishra; Katherine R Singleton; Minjae Yoo; Sonia M Leach; Eveline Farias-Hesson; Robert J Mason; Jaewoo Kang; Preveen Ramamoorthy; Jeffrey A Kern; Lynn E Heasley; James H Finigan; Aik Choon Tan
Journal:  Bioinformatics       Date:  2014-05-07       Impact factor: 6.937

8.  Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.

Authors:  Benjamin D Ferguson; Yi-Hung Carol Tan; Rajani S Kanteti; Ren Liu; Matthew J Gayed; Everett E Vokes; Mark K Ferguson; A John Iafrate; Parkash S Gill; Ravi Salgia
Journal:  Sci Rep       Date:  2015-06-15       Impact factor: 4.379

9.  Genetically Encoded FRET Biosensor for Visualizing EphA4 Activity in Different Compartments of the Plasma Membrane.

Authors:  Yijia Pan; Shaoying Lu; Lei Lei; Ilaria Lamberto; Yi Wang; Elena B Pasquale; Yingxiao Wang
Journal:  ACS Sens       Date:  2019-01-16       Impact factor: 7.711

10.  Osteopontin is a prognostic biomarker in non-small cell lung cancer.

Authors:  Ane Kongsgaard Rud; Kjetil Boye; Miriam Oijordsbakken; Marius Lund-Iversen; Ann Rita Halvorsen; Steinar K Solberg; Gisle Berge; Aslaug Helland; Odd Terje Brustugun; Gunhild M Mælandsmo
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.